Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha Maintenance for Favorable-Risk AML
NCT06802718Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2b in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Started Jan 2023; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06802718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06802718.